All News
Renal Impairment in Rheumatoid Arthritis
d
MedPage Today
Patients with highly active rheumatoid arthritis (RA) experienced faster declines in kidney function than those whose disease was under better control, analysis of a large registry indicated.
Read Article
All in the Family (8.23.2024)
Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.
Read Article
Studies on Psoriatic Arthritis Prevention
Psoriatic arthritis (PsA) is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched, largely using claims data or retrospective data sets.
Read Article
Sequential Belimumab and RTX in SLE
Could disease control in active SLE patients be improved by the sequential use of subcutaneous BEL and intravenous RTX? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
https://t.co/CO0ltRX9Eo https://t.co/zey2UE4BRu
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 919 RTX-treated GPA pts shows TMP-SMX prophylaxis (given to 31%) assoc w/ reduced serious infections (adj HR 0.5) and less outpatient infections (aHR 0.8). All 13 pneumocystis infx (PJP) occured in those not Rx w/ TMP-SMX. https://t.co/bO6oAHv7Lr https://t.co/fPntW75hnY
Dr. John Cush RheumNow ( View Tweet)
Cohort of 112 VEXAS pts: skin involvement common (83%), esp early w/ LCV (36%), neutrophilic (34%) or perivascular dermatitis (30%). p.Met41Leu variant w/ PMN (Sweets?) dermatitis (82%); p.Met41Val variant w/ vasculitic lesions (55%). 92% respond to pred https://t.co/2ACXCGRsi5 https://t.co/tYqA26AlaF
Dr. John Cush RheumNow ( View Tweet)
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome - genetic disease with estimated prevalence of 1 in 4269 in men >50 year: systemic inflammation, progressive bone marrow failure, and inflammatory cutaneous manifestations https://t.co/hSmE64xzcU https://t.co/gWh4rvaaS3
Dr. John Cush RheumNow ( View Tweet)
Gluten can be "a wicked antigen". Full read Review of the potential role of gluten in inflammation and autoimmunity. Undigested gluten peptides can be modified by luminal transglutaminase or delivered to gut mucosal immune cells https://t.co/eonHfpZZiN https://t.co/iKwbzg2Lbu
Dr. John Cush RheumNow ( View Tweet)
AR882, a URAT1 inhibitor, was given FDA Fast Track designation for potential treatment of clinically visible tophi in patients with gout. In the US 13 mill have gout & 2 mill have visible tophi. AR882 was presented at EULAR24 https://t.co/StvD3iz9AD https://t.co/G9SzxJysSD https://t.co/KcUSPVb5pn
Links:
Dr. John Cush RheumNow ( View Tweet)
2024 Update of EULAR recommendations for the Treatment of Systemic Sclerosis
https://t.co/52XEfgVCzZ https://t.co/d1zgTYUeOo
Dr. John Cush RheumNow ( View Tweet)
A Family History of Arthritis?
Using data from the population based All of Us Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome.
https://t.co/SApbPLHquQ https://t.co/hOamnYyRoz
Dr. John Cush RheumNow ( View Tweet)
Lipids and Inflammation in Rheumatoid Arthritis
In the realm of chronic inflammation, lipid abnormalities are well-recognized as pivotal contributors to the progression and clinical manifestations of atherosclerosis. Particularly in rheumatoid arthritis (RA), a systemic… https://t.co/zHKbBHlap8 https://t.co/KRIg1KYmcC
Dr. John Cush RheumNow ( View Tweet)
Longitudinal US RA Registry of 31129 #RA pts (148K Pt-Yrs F/U) shows Higher RA Dz activity assoc w/ eGFR decline & renal dysfunction. Compared to remission, pts in Hi Dz activity had HR 1.27 risk for CKD G3a (<60cc) & HR 1.93 for CKD 3b (<45cc/min) https://t.co/UaFINRzqoM https://t.co/XXQviVO6jU
Dr. John Cush RheumNow ( View Tweet)
Tyk2 inhibitor/Zasocitinib (TAK-279) effective in Psoriasis. Ph II RDBPCT of 259 pts w/ mod- severe plaque PsO showed 12 week PASI 75 success in 68% & 67% on 15 - 30 mg zasocitinib qd vs Placebo (18%). https://t.co/yyZwBYAP3H https://t.co/TvSSlEAKtR
Dr. John Cush RheumNow ( View Tweet)
Tobacco is a risk factor for hidradenitis suppurativa (HS). Korean population study finds 3761 HS out of 6 million. Those who quit smoking developed less HS (adj HR 0.68; 95% CI, 0.56-0.83) https://t.co/4HF0Z5HORk https://t.co/ZilX4EzAa9
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic Rx may be less effective in psoriasis pts who are older, smokers, w/ Hi BMI & prior biologic use. Metanalysis of 40 studies, 21 438 PSO pts, and PASI90 responses. Decr Response w/ age (OR 0.99), Biologics (0.44), BMI 30+ (0.57), smoking (0.81) https://t.co/uhFFIwNKB7 https://t.co/LaznQ0M9UG
Dr. John Cush RheumNow ( View Tweet)
Predictors of Pregnancy Outcomes in SLE
A review of preconception predictors of pregnancy outcomes in women with SLE highlighted lupus nephritis,chronic hypertension, SLE disease activity and secondary antiphospholipid syndrome as predictors of APO.
https://t.co/vA445kSe5t https://t.co/wGhLjCmJ3v
Dr. John Cush RheumNow ( View Tweet)
Pulse Steroids with Tocilizumab in Giant Cell Arteritis
A pilot study assessed pulse methoprednisolone with weekly subcutaneous TCZ in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued.
https://t.co/gGrSY3U1t9 https://t.co/zuspadaY9t
Dr. John Cush RheumNow ( View Tweet)
Overview of Cannabinoids for Rheumatic Pain disappoints because not much is really known or studied well. They may improve pain, but come w/ mild-mod side effects. Conflicting evidence contributes to practitioner and patient uncertainty https://t.co/eI07SXbbem https://t.co/ZDvdFcLXh4
Dr. John Cush RheumNow ( View Tweet)
HBV reactivation w/ Anti-IL17, IL12/23, IL23 & JAKi. Metanalysis of pts w/ chronic HBV infection (HBsAg+ or detectable HBV-DNA) and prior HBV infection (HBcAb+, HBsAg neg) shows more reactiv w/ chronic HBV (14% vs 5%), similar betw classes (0-4%) https://t.co/5Jgehb5gNg https://t.co/o0TuLEsMm9
Dr. John Cush RheumNow ( View Tweet)